Stock Mover of The Day: 1.92 is Bio-path Holdings Inc’s (NASDAQ:BPTH) Institutional Investor Sentiment – Post News

Post NewsStock Mover of The Day: 1.92 is Bio-path Holdings Inc’s (NASDAQ:BPTH) Institutional Investor SentimentPost NewsBio-Path Holdings, Inc. is a clinical and preclinical stage oncology focused antisense drug development company. The company has a market cap of $121.41 million. The Firm utilizes a technology that achieves systemic delivery for target specific protein …The Bio-Path Holdings Inc (BPTH) Decreased to “Sell” by The Zacks …DailyQuintBIO-PATH HOLDINGS, INC. (NASDAQ:BPTH) Files An 8-K Submission of Matters to a Vote of Security HoldersMarket ExclusiveBio-Path Holdings Inc. (BPTH) Moves Lower on Volume Spike for December 21Equities.comCommunity Financial Newsall 12 news articles »

Read More

Bio-Path Holdings Inc (BPTH) Lowered to “Sell” at Zacks Investment … – Community Financial News

Community Financial NewsBio-Path Holdings Inc (BPTH) Lowered to “Sell” at Zacks Investment …Community Financial NewsBio-Path Holdings logo Bio-Path Holdings Inc (NASDAQ:BPTH) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report …Zacks Investment Research downgraded Bio-Path Holdings Inc …Breaking Finance NewsBio-Path Holdings Inc. (BPTH) Soars 6.67% on December 19 …Equities.comall 3 news articles »

Read More

After-Hours Stock Movers 12/19: (CNAT) (IONS) Higher; (NPTN) (SCMP) (REN) Lower (more…) – StreetInsider.com

After-Hours Stock Movers 12/19: (CNAT) (IONS) Higher; (NPTN) (SCMP) (REN) Lower (more…)StreetInsider.comAZD8233 is designed to inhibit an undisclosed target to treat cardiovascular disease and is also the first of a new class of antisense drugs that uses both Ionis’ proprietary Generation 2.5 chemistry and its LIgand Conjugated Antisense or LICA technology.and more »

Read More

Triglycerides Fall in Phase 3 Trial of Novel Antisense Inhibitor – Medscape

MedscapeTriglycerides Fall in Phase 3 Trial of Novel Antisense InhibitorMedscapeVolanesorsen is an antisense drug designed to reduce triglyceride levels by targeting apolipoprotein C-III. Akcea, a wholly owned subsidiary of Ionis Pharmaceuticals (Carlsbad, CA), is developing the drug to treat patients with the rare metabolic …Akcea and Ionis Announce Positive Results from Compass Phase 3 Study of VolanesorsenPR Newswire (press release)Volanesorsen Appears Beneficial for Patients with Severe HypertriglyceridemiaMonthly Prescribing Reference (registration)all 7 news articles »

Read More

AstraZeneca uses Ionis to make sense from antisense – BioPharma Dive

Community Financial NewsAstraZeneca uses Ionis to make sense from antisenseBioPharma DiveAstraZeneca has completed IND-supporting studies for the antisense drug AZD4785 for KRAS-linked cancers and paid Ionis Pharmaceuticals a $28 million milestone payment. The big pharma is exercising its option to license IONIS-KRAS-2.5Rx originally …Ionis (IONS) Receives Milestone Payment from AstraZeneca …Zacks.comCompany Update (NASDAQ:IONS): Ionis Pharmaceuticals Inc and AstraZeneca Advance First Generation 2.5 LICA …Smarter Analystall 7 news articles »

Read More

Ionis nabs $28M milestone from AstraZeneca for licensing KRAS-targeting antisense candidate; shares up 5% premarket – Seeking Alpha

Frisco FastballIonis nabs $28M milestone from AstraZeneca for licensing KRAS-targeting antisense candidate; shares up 5% premarketSeeking AlphaIonis Pharmaceuticals (NASDAQ:IONS) is 5% premarket, albeit on only 699 shares, in response to its announcement that it has earned $28M from AstraZeneca (NYSE:AZN) triggered by its completion of IND-supporting studies and licensing of …Ionis Wins $28M Milestone Payment from AstraZenecaGenetic Engineering & Biotechnology NewsIonis Earns $28 Million from AstraZeneca for a New Drug to Treat CancerPR Newswire (press release)Ionis Pharmaceuticals to Host a Pipeline Update WebcastYahoo FinanceBenchmark Monitorall 24 news articles »

Read More

Bio-Path Holdings Inc. (BPTH) Upgraded to “Hold” by Zacks Investment Research – The Cerbat Gem

The Cerbat GemBio-Path Holdings Inc. (BPTH) Upgraded to “Hold” by Zacks Investment ResearchThe Cerbat GemBio-Path Holdings Company Profile. Bio-Path Holdings, Inc is a clinical and preclinical stage oncology focused antisense drug development company. The Company utilizes a technology that achieves systemic delivery for target specific protein inhibition …and more »

Read More

Novel drug rescues babies with fatal neurodegenerative disease – Science Magazine

Science MagazineNovel drug rescues babies with fatal neurodegenerative diseaseScience MagazineTheir collaboration led to the development of nusinersen, a snippet of modified RNA called an antisense oligonucleotide that intervenes in the transcription process to ensure that SMN-2 makes the full-length SMN protein. After extensive preclinical …’New dawn’ for spinal muscular atrophy treatmentmedwireNewsall 8 news articles »

Read More

BIO-PATH HOLDINGS, INC. (NASDAQ:BPTH) Files An 8-K … – Market Exclusive

Marea InformativeBIO-PATH HOLDINGS, INC. (NASDAQ:BPTH) Files An 8-K …Market ExclusiveBio-Path Holdings, Inc. is a clinical and preclinical stage oncology focused antisense drug development company. The Company utilizes a technology that …Bio-Path Holdings Inc (NASDAQ:BPTH) has been downgraded to …Breaking Finance NewsBio-Path Holdings Inc. (BPTH) Downgraded by Zacks Investment …Marea Informativeall 3 news articles »

Read More

Could new technique give citrus greening the red light? – Fresh Fruit Portal

Genetic Literacy ProjectCould new technique give citrus greening the red light?Fresh Fruit PortalThe group said preliminary results showed an increase in insect mortality and reduction of bacteria within citrus trees, which was the first evidence of the successful delivery of FANA Antisense Oligonucleotides (FANA ASOs) into plants through foliar …USDA and AUM LifeTech develop a novel Non-GMO RNA silencing approach against citrus greening with a goal to …The Daily Mealall 3 news articles »

Read More

USDA and AUM LifeTech develop a novel Non-GMO RNA silencing approach against citrus greening with a goal to … – PR Newswire (press release)

USDA and AUM LifeTech develop a novel Non-GMO RNA silencing approach against citrus greening with a goal to …PR Newswire (press release)Preliminary results showed an increase in insect mortality and reduction of bacteria within citrus trees. This is the first evidence of successful delivery of FANA Antisense Oligonucleotides (FANA ASOs) into plants through foliar sprays, root …

Read More

Short Interest Filing: It Seems Bio Path Holdings DE (NASDAQ:BPTH) Will Go Down. Just Reported More Shorted Shares – Post News

Post NewsShort Interest Filing: It Seems Bio Path Holdings DE (NASDAQ:BPTH) Will Go Down. Just Reported More Shorted SharesPost NewsBio-Path Holdings, Inc. is a clinical and preclinical stage oncology focused antisense drug development company. The company has a market cap of $125.30 million. The Firm utilizes a technology that achieves systemic delivery for target specific protein …

Read More

HMMR antisense RNA 1, a novel long noncoding RNA, regulates the progression of basal-like breast cancer cells – Dove Medical Press

HMMR antisense RNA 1, a novel long noncoding RNA, regulates the progression of basal-like breast cancer cellsDove Medical PressAbstract: Recently, accumulating evidence has suggested that long noncoding RNAs (lncRNAs) play crucial roles in carcinogenesis and cancer progression. Hyaluronan-mediated motility receptor (HMMR) is an essential cancer-related gene in basal-like …

Read More

‘Antisense’ compounds offer new weapon against influenza A – University of Rochester Newsroom

University of Rochester Newsroom’Antisense’ compounds offer new weapon against influenza AUniversity of Rochester NewsroomOf 14 antisense oligonucleotide sequences (ASOs) tested against Influenza A virus in a study by University researchers Luis Martinez-Sobrido and Douglas Turner and their collaborators, five were most effective. The five are underlined in this figure …

Read More

Insider Worth Mentioning: Ionis Pharmaceuticals Inc (NASDAQ:IONS)’s SVP – Antisense Research Frank Bennett Sold … – Thorold News

Thorold NewsInsider Worth Mentioning: Ionis Pharmaceuticals Inc (NASDAQ:IONS)’s SVP – Antisense Research Frank Bennett Sold …Thorold NewsIt was disclosed in a legal report that was submitted to the Security and Exchange Commission that Frank Bennett, who works for Ionis Pharmaceuticals Inc, and serves as SVP – Antisense Research did an insider sale on 11-11-2016. Frank sold 22,805 …Ionis Pharmaceuticals Reports Positive Clinical Data from IONIS-ANGPTL3-L RxPR Newswire (press release)Piper Jaffray Sings the Praises of Ionis Pharmaceuticals Inc (IONS) as a Top Mid-Cap Pick Following Management …Smarter Analystall 46 news articles »

Read More